Accolade, Inc. (ACCD)

NASDAQ: ACCD · IEX Real-Time Price · USD
8.34
-0.55 (-6.19%)
Dec 5, 2022 4:00 PM EST - Market closed
-6.19%
Market Cap 639.54M
Revenue (ttm) 350.38M
Net Income (ttm) -401.40M
Shares Out 70.48M
EPS (ttm) -1.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 827,648
Open 8.81
Previous Close 8.89
Day's Range 8.12 - 8.87
52-Week Range 4.61 - 27.74
Beta 1.48
Analysts Buy
Price Target 14.21 (+70.4%)
Earnings Date Jan 9, 2023

About ACCD

Accolade, Inc., together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves emplo... [Read more]

Industry Health Care Technology
IPO Date Jul 2, 2020
Employees 2,350
Stock Exchange NASDAQ
Ticker Symbol ACCD
Full Company Profile

Financial Performance

In 2021, Accolade's revenue was $310.02 million, an increase of 81.98% compared to the previous year's $170.36 million. Losses were -$123.12 million, 143.1% more than in 2020.

Financial Statements

Analyst Forecast

According to 23 analysts, the average rating for ACCD stock is "Buy." The 12-month stock price forecast is 14.21, which is an increase of 70.38% from the latest price.

Price Target
$14.21
(70.38% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Accolade Champions Health Equity and Welcomes FOLX Health to Trusted Partner Ecosystem at HLTH 2022

Chief Medical Officer Dr. Shantanu Nundy and Dr. Jay Bhatt, Managing Director at Deloitte, explore the role of employers in removing barriers to equitable healthcare; Accolade welcomes a new trusted par...

3 weeks ago - PRNewsWire

Accolade (ACCD) Reports Q2 Loss, Tops Revenue Estimates

Accolade (ACCD) delivered earnings and revenue surprises of 7.04% and 5.68%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Accolade Announces Results for Fiscal Second Quarter 2023

SEATTLE, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal second quarter ended August 31, 2022.

1 month ago - GlobeNewsWire

Accolade (ACCD) Expected to Beat Earnings Estimates: Should You Buy?

Accolade (ACCD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Accolade to Announce Fiscal Second Quarter 2023 Financial Results

SEATTLE, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 600 employers and millions of members, today announced that it will release fiscal secon...

2 months ago - GlobeNewsWire

Carrum Health Selected as Trusted Partner by Accolade to Help Employers Achieve Immediate and Tangible Cost Savings

Carrum's Value-Based Centers of Excellence Solution Now Easily Accessible to Accolade Clients for More Affordable, Appropriate Surgical Care SAN FRANCISCO , Aug. 17, 2022 /PRNewswire/ -- Carrum Health ,...

3 months ago - PRNewsWire

Accolade appoints new chief information security officer

With the addition of senior vice president and CISO, Kelli Burns, Accolade further elevates its focus on trusted, personalized relationships through exceptional information security for its members and ...

4 months ago - PRNewsWire

Priority Health announces launch of new health navigation solution, PriorityGPS™

GRAND RAPIDS, Mich.--(BUSINESS WIRE)--Priority Health, a nationally recognized nonprofit health plan, announced today the launch of PriorityGPS™, an integrated health navigation and advocacy solution. P...

4 months ago - Business Wire

Here's Why Accolade Shares Are Trading Higher Today

Needham analyst Ryan MacDonald reiterated a Buy rating on Accolade, Inc (NASDAQ: ACCD) with a price target of $12. Following a problematic 4QF22, he noted that Accolade bounced back nicely in 1QF23 as t...

5 months ago - Benzinga

Micron, Akebia Therapeutics And 3 Stocks To Watch Heading Into Friday

Some of the stocks that may grab investor focus today are: Micron Technology Inc (NASDAQ: MU) reported upbeat financial results for its third quarter, but issued weak guidance for its fourth quarter. Mi...

Other symbols: AKBAMUCOSTHI
5 months ago - Benzinga

Accolade (ACCD) Reports Q1 Loss, Tops Revenue Estimates

Accolade (ACCD) delivered earnings and revenue surprises of 45.21% and 3.80%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Accolade Announces Results for Fiscal First Quarter 2023

SEATTLE, June 30, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal first quarter ended May 31, 2022.

5 months ago - GlobeNewsWire

Accolade (ACCD) Stock Jumps 7.2%: Will It Continue to Soar?

Accolade (ACCD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

5 months ago - Zacks Investment Research

Accolade to showcase Personalized Healthcare for health plans at AHIP 2022

Accolade and Priority Health will discuss how Personalized Healthcare can deliver value for health plans seeking virtual first solutions for whole person care. SEATTLE , June 21, 2022 /PRNewswire/ -- Ac...

5 months ago - PRNewsWire

Accolade to Announce Fiscal First Quarter 2023 Financial Results

SEATTLE, June 21, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 600 employers and millions of members, today announced that it will release fiscal first ...

5 months ago - GlobeNewsWire

Accolade Announces Participation in June Investor Conferences

SEATTLE, June 02, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will participate in the following upcoming investor conferences. A webcast and replay of each event will ...

6 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Accolade, Inc. - ACCD

NEW YORK , May 30, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Accolade, Inc. ("Accolade" or the "Company") (NASDAQ: ACCD). Such investors are advised to contact...

6 months ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors Accolade, Inc. - ACCD

New York, New York--(Newsfile Corp. - May 28, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Accolade, Inc. ("Accolade" or the "Company") (NASDAQ: ACCD). Such investors are advi...

6 months ago - Newsfile Corp

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Accolade, Inc. Investors to Inquire About Securities Class Action Investi...

NEW YORK , May 17, 2022 /PRNewswire/ -- WHY: New York, N.Y., May 17, 2022.

6 months ago - PRNewsWire

Accolade Expands Mental Health Integrated Care Offering to Adolescents and Teens

Accolade and Headspace Health to increase access to preventative resources and mental health services for adolescents and teens amid national mental health crisis SEATTLE , May 10, 2022 /PRNewswire/ -- ...

6 months ago - PRNewsWire

Accolade Announces Participation in May Investor Conferences

SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will participate in the following upcoming investor conferences. A webcast and replay of each event will b...

6 months ago - GlobeNewsWire

Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Accolade, Inc. with Losses of $100,000 to...

Los Angeles, California--(Newsfile Corp. - May 4, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Accolade...

7 months ago - Newsfile Corp

Investigation Notice: The Schall Law Firm Encourages Investors in Accolade, Inc. with Losses of $100,000 to Contact t...

Los Angeles, California--(Newsfile Corp. - May 3, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Accolade...

7 months ago - Newsfile Corp

Accolade Launches Medication Integrated Care to Address Prescription Drug Costs and Complications

Medication Integrated Care combines pharmacist-led medication therapy management with advanced analytics powered by Rx Savings Solutions to help employers reach individuals most likely to struggle with ...

7 months ago - PRNewsWire

Why Is Accolade (ACCD) Stock Up Today?

Today, investors in Accolade and ACCD stock have something to cheer, following a rather dismal end to last week. The post Why Is Accolade (ACCD) Stock Up Today?

7 months ago - InvestorPlace